Abstract: Objective To study the curative effect of neoadjuvant chemotherapy of TAC in the treatment of triple-negative breast cancer. Methods To accept 4～6 cycles TAC neoadjuvant chemotherapy of 63 cases of TNBC were retrospectively study. Analysis the near-term and long-term curative effects. Results Of the 63 patients,the overal response rate(RR) was 96.83%, including complete response(CR) was 57.14%（36/63)，partial response(PR) was 39.68%(25/63）；the major complications included neutropenia（57.14%）,nertropenia associated fever（39.68%）,nausea and vomiting（52.38%）,diarrhea（22.22%）,oral mucositis （20.63%）,malaise and weakness（15.87%）.Postoperative death was 7 cases，There were 8 cases of local recurrence and 21 cases of remote metastasis. The overall 3-year survival rate was 88.89%. Conclusion TAC neoadjuvant chemotherapy could improve the curative effect of TNBC with better quality of life and promoted 3-year survival rate.

Key words: TAC, Triple negative breast cancer, Neoadjuvant chemotherapy

摘要： 【摘要】目的 探讨TAC新辅助化疗方案治疗三阴性乳腺癌（triple-negative breast cancer，TNBC）的临床疗效。方法 对接受4～6个周期TAC新辅助化疗方案治疗的63例TNBC进行回顾性研究，分析近远期化疗疗效。结果 63例患者总有效率(RR)96.83%，其中完全缓解(CR)57.14%（36/63)，部分缓解(PR)39.68%(25/63）。主要不良反应中性粒细胞减少36例（57.14%），中性粒细胞减少性发热25例（39.68%），恶心呕吐33例（52.38%），腹泻14例（22.22%），口腔黏膜炎13例（20.63%），乏力虚弱10例（15.87%）。术后死亡7例，局部复发8例，远处转移21例，3年生存率88.89%。结论 应用TAC新辅助化疗方案能提高TNBC治疗效果，改善患者生活质量，提高3年生存率。

关键词: TAC方案, 三阴性乳腺癌, 新辅助化疗